Lymph Cancer Testing Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Lymph Cancer Testing Market is segmented By Test Type (Sentinel lymph node Biopsy, Blood Tests, CT Scan & PET Scan, Others), By Disease Type (Non–Hodgkin Lymphoma, Hodgkin Lymphoma), By End-User (Hospitals, Diagnostic Centers, Research and Educational Institutions, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Global Lymph Cancer Testing Market reached US$ 8.5 billion in 2023 and is expected to reach US$ 19.63 billion by 2031, growing at a CAGR of 11.3% during the forecast period 2024-2031.

Lymphoma is a type of blood cancer that affects the immune system. It specifically affects white blood cells called lymphocytes, an important part of the immune system. Lymphoma is also called a cancer of the lymphatic system, or lymphatic cancer. In lymphoma, the development of the lymphocytes becomes very uneven. The lymphocytes don’t work properly and tend to multiply out of control.

There are two main types of lymphoma, Hodgkin lymphoma and non-Hodgkin lymphoma. Both types affect the lymphocytes. Over 14,000 people are diagnosed with lymphoma each year in the UK, making it the most common blood cancer. A common lymphoma symptom is lumps. These are swollen lymph nodes (glands). One may get painless swellings on the neck, collarbone, armpit, groin, or other body parts. Some swollen lymph nodes can press on organs and cause pain in the chest, coughing, breathlessness, or pain in the stomach area.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing prevalence of lymph cancers

The demand for the global lymph cancer testing market is driven by multiple factors. The rising prevalence of lymph cancers propels the market growth. 

For instance, according to an article published by the American Cancer Society in January 2024, non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. It is estimated that about 80,620 people (44,590 males and 36,030 females) will be diagnosed with NHL. This includes both adults and children.

It is estimated that about 20,140 people will die from this cancer (11,780 males and 8,360 females). Overall, the chance that a man will develop NHL in his lifetime is about 1 in 42; for a woman, the risk is about 1 in 52. However, each person’s risk can be affected by several risk factors. NHL can occur at any age. It is one of the more common cancers among children, teens, and young adults. Still, the risk of developing NHL increases throughout life, and more than half of people are 65 or older when they are first diagnosed.

Restraints

Factors such as high cost associated with the testing, lack of healthcare infrastructure, shortage of skilled professionals, and stringent regulatory requirements for the approval of new techniques are expected to hamper the market.

Market Segment Analysis

The global lymph cancer testing market is segmented based on test type, disease type, end-user, and region.

The segment CT scan and PET scan accounted for approximately 43.8% of the global lymph cancer testing market share

The CT scan and PET scan segment is expected to hold the largest market share over the forecast period. In this segment, the technological advancements, and rising funds for private manufacturers for research work would drive this market. 

Lymphoma can affect different areas at the same time. Whole-body PET/CT can find sites affected by lymphoma such as the bone marrow, liver, and spleen. It’s the most accurate imaging method for staging and re-staging lymphoma and provides a baseline for subsequent evaluation of therapy response and cancer recurrence. PET stands for positron emission tomography. This can help to give a clearer picture of which areas of the body are affected by lymphoma. 

Fluoro-deoxy-glucose (FDG) is the radiotracer most often used in PET scans.  The image processing techniques, target delineation methodologies, and PET-guided protocols for biologically guided radiation therapy and PET-adaptive therapy are important factors in this regard. The integration of PET with computed tomography (CT) in PET/CT scans enables precise localization of lesions through the accumulation of F-fluoro-d-glucose. PET exhibits superior reliability in diagnosing lymph node metastases compared to conventional imaging modalities such as computed tomography or MRI, positioning it as a valuable non-invasive diagnostic tool.

Market Geographical Share

North America accounted for approximately 42.1% of the global lymph cancer testing market share 

North America region is expected to hold the largest market share over the forecast period. The rising incidence of lymph cancer, technological advancements, and growing awareness among people, in this region, help to propel the market.

For instance, in June 2024, Roche launched an in vitro diagnostic assay, Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries that accept the EU CE mark. The Ventana B-cell lymphoma diagnostic assay is designed to qualitatively detect Kappa mRNA and Lambda mRNA. The test detects the presence of B-cell lymphomas and plasma cell neoplasms in formalin-fixed, paraffin-embedded (FFPE) human bone marrow and lymphoid tissue.

The increased sensitivity of the test allows for the assessment of more than 60 subtypes of B-cell lymphoma and plasma cell neoplasms on a single tissue slide. The test can also be performed on small biopsies and formalin-fixed tissue, thereby reducing the need for a fresh tissue sample, which may not be available, especially if lymphoma was not originally suspected. 

Moreover, according to the Canadian Cancer Society, it is estimated that 11,700 Canadians will be diagnosed with non-Hodgkin lymphoma. 3,100 Canadians will die from non-Hodgkin lymphoma. 6,600 men will be diagnosed with non-Hodgkin lymphoma and 1,800 will die from it. 5,100 women will be diagnosed with non-Hodgkin lymphoma and 1,300 will die from it. 

Market Segmentation

By Test Type

• Sentinel lymph node Biopsy
• Blood Tests
• CT Scan & PET Scan
• Others 

By Disease Type

• Non-Hodgkin lymphoma
• Hodgkin lymphoma

By End-User

• Hospitals
• Diagnostic Centers
• Research and Educational Institutions
• Others

By Region

• North America 
• U.S.
• Canada
• Mexico 
• Europe
• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe 
• South America 
• Brazil
• Argentina
• Rest of South America 
• Asia-Pacific 
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 
• Middle East and Africa

Market Competitive Landscape

The major global players in the global lymph cancer testing market include GE Healthcare, Siemens Healthineer, Abbott Laboratories, Canon Medical Systems, Agilent Technologies, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics, and Bio-Rad Laboratories among others.

Key Developments

• In March 2024, SCOR announced the launch of the Vitae Lymphoma Risk Calculator, a new addition to the Group’s biometric risk calculator series that aims to expand protection coverage to people with cancer and other critical diseases. 
• In November 2023, Roswell Park launched an advanced, high-speed blood cancer test. PanHeme is the test that uses next-generation gene sequencing technology to diagnose blood cancers like leukemia, and lymphoma and identify mutations in hundreds of genes in under 72 hours, a dramatic improvement from the three- to four-week wait time for current molecular testing.

Why Purchase the Report?

• To visualize the global lymph cancer testing market segmentation based on test type, disease type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global lymph cancer testing market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global lymph cancer testing market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies